| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.12 | 6e-05 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.12 | 7e-05 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.14 | 7e-05 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.13 | 7e-05 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.15 | 8e-05 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 8e-05 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.12 | 9e-05 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.13 | 9e-05 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.19 | 9e-05 |